Iatrogenic botulism after botulinum toxin type A injections

Clicks: 288
ID: 267469
2010
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #2 of 2 articles by views in clinical neuropharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Therapeutic use of botulinum toxin type A (BT/A) is well known, effective, and safe. Iatrogenic botulism that presents with generalized weakness, dysphagia, and respiratory distress is a rare but significant complication in BT/A treatment. In this study, we report 4 patients who developed iatrogenic …
Reference Key
a2010clinicaliatrogenic Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Coban A;Matur Z;Hanagasi HA;Parman Y;;
Journal clinical neuropharmacology
Year 2010
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/20150804
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome adult female case reports aged time factors botulinum toxins botulism / etiology* type a / adverse effects* pmid:20150804 doi:10.1097/wnf.0b013e3181d479e0 arzu coban zeliha matur yesim parman anti-dyskinesia agents / adverse effects* anti-dyskinesia agents / therapeutic use blepharospasm / drug therapy type a / therapeutic use drug monitoring iatrogenic disease* muscle spasticity / drug therapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.